Home > Boards > US OTC > Biotechs > Revance Therapeutics, Inc. (RVNC)

EOLS ITC decision scheduled for tomorrow. Should

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
rwwine Member Profile
 
Followed By 4
Posts 570
Boards Moderated 0
Alias Born 10/27/03
160x600 placeholder
Revance to Participate in Upcoming Virtual Healthcare Conferences Business Wire - 5/26/2021 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2021 8:04:50 AM
Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection Business Wire - 5/26/2021 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2021 4:42:24 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/10/2021 4:11:10 PM
Revance Therapeutics EPS beats by $0.11, beats on revenue Seeking Alpha - 5/10/2021 4:10:14 PM
Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update Business Wire - 5/10/2021 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:15:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:13:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:11:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:09:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:07:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:04:54 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2021 4:07:04 PM
Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021 Business Wire - 5/3/2021 8:00:00 AM
Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA’s 24-Week Long Durati... Business Wire - 4/27/2021 4:05:00 PM
Enrollment underway in Revance Therapeutics' late-stage DaxibotulinumtoxinA study Seeking Alpha - 4/27/2021 8:35:27 AM
Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines & Cervical Dystonia in China by Fosun Pha... Business Wire - 4/27/2021 8:00:00 AM
Revance to Present Data on DaxibotulinumtoxinA for Injection & Hyaluronic Acid Fillers at American Academy of Dermatology VMX... Business Wire - 4/23/2021 8:00:00 AM
Revance signs supply agreement with contract manufacturer Lyophilization Seeking Alpha - 4/12/2021 4:32:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/6/2021 7:42:27 PM
Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference Business Wire - 4/6/2021 4:05:00 PM
Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at th... Business Wire - 4/1/2021 8:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 3/24/2021 5:25:49 PM
Fortune Names Revance to the Top 10 Best Workplaces in Biopharma in 2021 Business Wire - 3/22/2021 4:05:00 PM
rwwine   Tuesday, 12/15/20 11:25:35 AM
Re: DewDiligence post# 1688
Post # of 1932 
EOLS ITC decision scheduled for tomorrow. Should be interesting!!

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences